Completed PHASE2 INTERVENTIONAL 3-arm NCT00244751

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy

Sponsor: GlaxoSmithKline

Conditions Cirrhosis, Liver

Interventions GI262570 0.5 mg GI262570 1.0 mg Placebo

Updated 8 times since 2017 Last updated: Nov 8, 2017 Started: Nov 2, 2005 Primary completion: Mar 13, 2008 Completion: Mar 13, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00244751, this PHASE2 trial focuses on Cirrhosis, Liver and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Feb 2026 [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Dec 2017 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Auckland, New Zealand , Bakersfield, United States , Bandar Tun Razak, Cheras, Malaysia , Berlin, Germany , Binghamton, United States , Birmingham, United States , Bonn, Germany , Boston, United States and 91 more locations